<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">KISS, IGOR</style></author><author><style face="normal" font="default" size="100%">MLCOCHOVA, JITKA</style></author><author><style face="normal" font="default" size="100%">BORTLICEK, ZBYNEK</style></author><author><style face="normal" font="default" size="100%">POPRACH, ALEXANDR</style></author><author><style face="normal" font="default" size="100%">DRABEK, JIRI</style></author><author><style face="normal" font="default" size="100%">VYCHYTILOVA-FALTEJSKOVA, PETRA</style></author><author><style face="normal" font="default" size="100%">SVOBODA, MAREK</style></author><author><style face="normal" font="default" size="100%">BUCHLER, TOMAS</style></author><author><style face="normal" font="default" size="100%">BATKO, STANISLAV</style></author><author><style face="normal" font="default" size="100%">RYSKA, ALES</style></author><author><style face="normal" font="default" size="100%">HAJDUCH, MARIAN</style></author><author><style face="normal" font="default" size="100%">SLABY, ONDREJ</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type &lt;em&gt;KRAS&lt;/em&gt; Colorectal Cancer Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4955-4959</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><issue><style face="normal" font="default" size="100%">9</style></issue><abstract><style  face="normal" font="default" size="100%">Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting. Patients and Methods: In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab. Results: We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab. Conclusion: It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab.</style></abstract></record></records></xml>